The major effort of the Duke BTIP is the evaluation of novel immunotherapeutic treatments for adult and pediatric malignant brain tumors. Several phase I and II clinical trials are operative within our program that include peptide vaccines, tumor RNA-loaded dendritic cell vaccines, and adoptive T cell therapy.
The Duke Brain Tumor Immunotherapy Program maintains the capacity to produce clinical-grade human products for use in cellular therapy trials within an FDA-approved cell processing facility. Translational research efforts in brain tumor immunotherapy are supported by a strong preclinical program investigating basic aspects of tumor immunology, as well as the preclinical evaluation of novel immunotherapeutic treatments in experimental mice.
In several syngeneic, transgenic and human xenograft models of adult, pediatric brain tumors in order to investigate mechanisms of tumor-induced immunosuppression and advance new immunologic treatments for malignant brain tumors into early phase clinical trials.